INTRODUCTION {#s1}
============

Gastric cancer, also known as stomach cancer, starts as an infectious disease that drives the development of chronic inflammation and ulcerated lesions, located within the stomach wall lining. In most cases of gastric cancer, these lesions are morphologically defined as epithelial carcinomas \[[@R1]--[@R3]\]. During tumor progression, the gastric cancer cells migrate and metastasize to the lymph nodes, the abdomen, bones, lungs and the liver. The most common etiology of gastric cancer is chronic infection with *Helicobacter pylori*, a bacterium, which represents ∼50-70% of the cases \[[@R4]--[@R6]\]. Classic symptoms consist of "heartburn", abdominal pain, nausea and vomiting, as well as anemia and occult blood in the feces. The diagnosis of gastric cancer is confirmed by an endoscopic biopsy, revealing an invasive carcinoma. The disease is most common in Asian countries, especially in South Korea and Japan, among others \[[@R1]--[@R6]\].

Unfortunately, the 5-year survival rates for gastric cancer patients vary widely, from as low as 15% to as high as 60%. As such, more effective biomarkers are urgently needed for the early stratification of gastric cancer patients, into low-risk and high-risk groups at diagnosis. Here, we directly tested the hypothesis that markers of mitochondrial biogenesis and respiratory function may have significant prognostic value in the early identification of high-risk gastric cancer patients, with increased tumor progression and poor overall survival.

More specifically, we employed a bioinformatics approach to determine the prognostic utility of nuclear-encoded mitochondrial mRNA species in predicting clinical outcome. Our results indicate that ∼75 individual mitochondrial gene probes can be effectively used, to predict progression and survival in gastric cancer patients. As a result, we propose the idea that mitochondria are novel therapeutic targets for drug discovery, aimed at optimizing the effectiveness of gastric cancer therapy \[[@R7]--[@R9]\].

RESULTS {#s2}
=======

Prognostic value of proliferative and inflammatory markers in gastric cancer patients {#s2_1}
-------------------------------------------------------------------------------------

Here, we used publically available transcriptional profiling data from the tumors of gastric cancer patients, with 5 years of follow-up data, to identify new potential biomarkers (Figure [1](#F1){ref-type="fig"}). As proliferative biomarkers are often used as clinical endpoints in patient trials, we first assessed the prognostic value of Ki67 and PCNA, in this patient population. Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"} both show the prognostic value of these markers. The hazard-ratios for Ki67 and PCNA were 1.79 and 1.86, respectively, for time to first progression (FP).

![A bio-informatics approach to gastric cancer marker discovery\
We chose to focus on gastric cancer patients, with 5-years of follow-up data (*N* = 359). In this context, we evaluated the prognostic value of mitochondrial markers for predicting time to first progression and overall survival.](oncotarget-08-67117-g001){#F1}

###### Prognostic value of Ki67 in gastric cancer

  Gene Probe ID   Symbol   Hazard-Ratio   Log-Rank Test
  --------------- -------- -------------- ---------------
  212020_s\_at    MKI67    1.92           1e-06
  212023_s\_at    MKI67    1.92           2.7e-07
  212022_s\_at    MKI67    1.83           1.9e-06
  212021_s\_at    MKI67    1.60           0.002
  **Combined**             **1.79**       **6.2e-06**

###### Prognostic value of PCNA and CD163 in gastric cancer

  Gene Probe ID   Symbol   Hazard-Ratio   Log-Rank Test
  --------------- -------- -------------- ---------------
  217400_at       PCNA     1.86           6.5e-06
  216233_at       CD163    1.46           0.003

![Markers of proliferation and inflammation predict poor clinical outcome in gastric cancer patients\
We assessed the predictive value of Ki67 and PCNA in *N* = 359 gastric cancer patients. **A.** Note that high transcript levels of Ki67 and PCNA are associated with significantly reduced time to first progression. Note that the official gene name for the Ki67 protein is MKI67. **B.** Note that that high transcript levels of CD163 are associated with significantly reduced time to first progression.](oncotarget-08-67117-g002){#F2}

We also assessed the prognostic value of a macrophage-specific marker of inflammation, namely CD163. Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"} show that CD163 effectively predicted time to first progression, with a hazard-ratio of 1.46. Thus, conventional markers of proliferation and inflammation predict overall survival in gastric cancer patients.

Prognostic value of individual mitochondrial markers {#s2_2}
----------------------------------------------------

To evaluate the hypothesis that elevated mitochondrial mass, biogenesis and function somehow contributes towards poor clinical outcome in gastric cancer patients, we also determined the prognostic value of individual mitochondrial markers.

First, we examined the behavior of mitochondrial membrane proteins and HSPs/chaperones. Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"} both show that VDAC3 and IMMT had the best prognostic value, with a hazard-ratio of up to 2.22 (p\<1.4e-09). HSPD1 and members of the TIMM and TOMM gene families also had prognostic value; SOD2 also had significant value. Positive results were also obtained with DNA-PK (PRKDC), a kinase that maintains the integrity and copy number of the mitochondrial genome (mt-DNA).

###### Prognostic value of mitochondrial HSPs and other mitochondrial proteins

  Gene Probe ID                                       Symbol    Hazard-Ratio   Log-Rank Test
  --------------------------------------------------- --------- -------------- ---------------
  **Heat Shock Proteins and Chaperones (4 probes)**                            
  200807_s\_at                                        HSPD1     1.83           1.9e-06
  200806_s\_at                                        HSPD1     1.56           0.003
  200691_s\_at                                        HSPA9     1.61           0.0002
  205565_s\_at                                        FXN       1.38           0.01
  **Membrane Proteins (9 probes)**                                             
  208844_at                                           VDAC3     2.22           1.4e-09
  211662_s\_at                                        VDAC2     1.51           0.002
  200955_at                                           IMMT      2.20           2.4e-09
  218118_s\_at                                        TIMM23    1.91           4.2e-07
  218408_at                                           TIMM10    1.88           1.4e-06
  218357_s\_at                                        TIMM8B    1.49           0.002
  201821_s\_at                                        TIMM17A   1.33           0.025
  201870_at                                           TOMM34    1.95           5.1e-07
  202264_s\_at                                        TOMM40    1.44           0.009
  **Mitochondrial Anti-Oxidants (2 probes)**                                   
  215223_s\_at                                        SOD2      1.72           2.1e-05
  215078_at                                           SOD2      1.70           2.9e-05
  **Mitochondrial Genome Maintenance (3 probes)**                              
  208694_at                                           PRKDC     2.05           1.2e-07
  210543_s\_at                                        PRKDC     1.78           6.9e-06
  215757_at                                           PRKDC     1.47           0.003

![Mitochondrial membrane proteins and PRKDC are associated with poor clinical outcome in gastric cancer patients\
**A.** Note that that high transcript levels of VDAC3 and IMMT are associated with significantly reduced time to first progression. **B.** Note that that high transcript levels of PRKDC are associated with significantly reduced time to first progression.](oncotarget-08-67117-g003){#F3}

Next, we determined the prognostic value of mitochondrial ribosomal proteins (MRPs), which are essential for mitochondrial biogenesis (Table [4](#T4){ref-type="table"}). Twelve components of the large subunit (MRPLs) showed significant prognostic value, with hazard-ratios between 2.17 and 1.29. Notably, MRPL28 had the best prognostic value. Eight different components of the small subunit (MRPSs) showed significant prognostic value, with hazard-ratios between 1.89 and 1.36. As a result, twenty different MRPs all predicted reduced time to first progression. Representative examples of Kaplan-Meier curves are shown in Figure [4](#F4){ref-type="fig"}, panels A & B.

###### Prognostic value of mitochondrial ribosomal proteins

  Gene Probe ID                             Symbol   Hazard-Ratio   Log-Rank Test
  ----------------------------------------- -------- -------------- ---------------
  **Large Ribosomal Subunit (12 probes)**                           
  204599_s\_at                              MRPL28   2.17           1.2e-08
  221997_s\_at                              MRPL52   2.12           3.2e-09
  222216_s\_at                              MRPL17   1.68           0.0001
  220527_at                                 MRPL20   1.67           0.0002
  217907_at                                 MRPL18   1.62           0.0004
  218887_at                                 MRPL2    1.60           0.0002
  203931_s\_at                              MRPL12   1.56           0.001
  208787_at                                 MRPL3    1.53           0.0007
  217919_s\_at                              MRPL42   1.52           0.002
  218049_s\_at                              MRPL13   1.47           0.008
  218281_at                                 MRPL48   1.40           0.009
  213897_s\_at                              MRPL23   1.29           0.049
  **Small Ribosomal Subunit (8 probes)**                            
  215919_s\_at                              MRPS11   1.89           5.1e-07
  213840_s\_at                              MRPS12   1.84           1.5e-06
  210008_s\_at                              MRPS12   1.47           0.004
  204330_s\_at                              MRPS12   1.37           0.015
  204331_s\_at                              MRPS12   1.37           0.037
  203800_s\_at                              MRPS14   1.53           0.002
  219220_x\_at                              MRPS22   1.44           0.005
  219819_s\_at                              MRPS28   1.42           0.01
  218112_at                                 MRPS34   1.36           0.02

![Mitochondrial ribosomal proteins (MRPs) are associated with poor clinical outcome in gastric cancer patients\
**A.** Note that high transcript levels of MRPL28 and MRPL52 predict significantly reduced time to first progression. **B.** Similarly, high transcript levels of MRPS11 and MRPS12 predict significantly reduced time to first progression.](oncotarget-08-67117-g004){#F4}

In addition, we evaluated the prognostic value of members of the OXPHOS complexes I-V. These results are summarized in Table [5](#T5){ref-type="table"}. Interestingly, 37 different gene probes for the OXPHOS complexes showed hazard-ratios between 2.27 and 1.30. NDUFS5 (complex I) had the best prognostic value (HR=2.27; p=6e-10). COX5B (complex IV) and ATP5O (complex V) also showed significant prognostic value (HR=2.14; p=1.4e-08 *versus* HR=2.22; p=2.1e-10). Kaplan-Meier analysis for components of complex I and II are shown in Figure [5A, 5B](#F5){ref-type="fig"}, while results with complex III and IV are shown in Figure [6A, 6B](#F6){ref-type="fig"}. Results with complex V are highlighted in Figure [7](#F7){ref-type="fig"}.

###### Prognostic value of mitochondrial OXPHOS complexes

  Gene Probe ID                Symbol   Hazard-Ratio   Log-Rank Test
  ---------------------------- -------- -------------- ---------------
  **Complex I (11 probes)**                            
  201757_at                    NDUFS5   2.27           6e-10
  215850_s\_at                 NDUFA5   1.93           2.1e-07
  208969_at                    NDUFA9   1.92           1.5e-06
  203606_at                    NDUFS6   1.74           7.9e-05
  214241_at                    NDUFB8   1.67           5.7e-05
  203371_s\_at                 NDUFB3   1.51           0.002
  218226_s\_at                 NDUFB4   1.49           0.003
  202001_s\_at                 NDUFA6   1.37           0.02
  218160_at                    NDUFA8   1.31           0.04
  202785_at                    NDUFA7   1.31           0.04
  218563_at                    NDUFA3   1.30           0.04
  **Complex II (1 probe)**                             
  214166_at                    SDHB     1.40           0.009
  **Complex III (2 probes)**                           
  207618_s\_at                 BCS1L    1.76           7.1e-06
  202233_s\_at                 UQCR8    1.51           0.001
  **Complex IV (10 probes)**                           
  213736_at                    COX5B    2.14           1.4e-08
  218057_x\_at                 COX4NB   1.94           7.7e-07
  201754_at                    COX6C    1.74           7.1e-05
  201441_at                    COX6B1   1.67           0.0001
  200925_at                    COX6A1   1.64           8.8e-05
  203880_at                    COX17    1.60           0.0003
  217451_at                    COX5A    1.49           0.006
  202110_at                    COX7B    1.42           0.01
  217249_x\_at                 COX7A2   1.33           0.035
  216003_at                    COX10    1.33           0.046
  **Complex V (13 probes)**                            
  221677_s\_at                 ATP5O    2.22           2.1e-10
  207552_at                    ATP5G2   1.90           7.5e-06
  207335_x\_at                 ATP5I    1.84           8.4e-06
  217801_at                    ATP5E    1.64           0.0002
  208972_s\_at                 ATP5G1   1.51           0.002
  210149_s\_at                 ATP5H    1.49           0.003
  202961_s\_at                 ATP5J2   1.47           0.004
  210453_x\_at                 ATP5L    1.45           0.006
  207573_x\_at                 ATP5L    1.44           0.01
  208746_x\_at                 ATP5L    1.40           0.009
  213366_x\_at                 ATP5C    1.33           0.03
  206993_at                    ATP5S    1.29           0.04
  213366_x\_at                 ATP5C1   1.33           0.03

![Mitochondrial complex I and II proteins are associated with poor clinical outcome in gastric cancer patients\
**A.** Note that high levels of NDUFS5 and NDUFA5 predict significantly reduced time to first progression. **B.** Similarly, high levels of SDHB predict significantly reduced time to first progression.](oncotarget-08-67117-g005){#F5}

![Mitochondrial complex III and IV proteins are associated with poor clinical outcome in gastric cancer patients\
**A.** Note that high levels of BCS1L and UQCR8 predict significantly reduced time to first progression. **B.** Similarly, high levels of COX5B and COX4NB predict reduced time to first progression.](oncotarget-08-67117-g006){#F6}

![Mitochondrial complex V proteins are associated with poor clinical outcome in gastric cancer patients\
Note that high levels of ATP5O and ATP5G2 predict significantly reduced time to first progression.](oncotarget-08-67117-g007){#F7}

Prognostic value of a short gastric (Ga) mito-signature {#s2_3}
-------------------------------------------------------

To increase the prognostic significance of these unique mitochondrial markers, we then combined the most promising markers to create a new gastric mitochondrial gene signature.

More specifically, Ga-Mito-Signature-1 contains 8 genes (NDUFS5, VDAC3, ATP5O, IMMT, MRPL28, COX5B, MRPL52, PRKDC). Importantly, Ga-Mito-Signature-1 yielded a significantly improved hazard-ratio for time to first progression (FP) (HR=2.77; p=1.4e-14), as well as for overall survival (OS) (HR=2.01; p=6e-11). These results are summarized in Table [6](#T6){ref-type="table"} and highlighted in Figure [8](#F8){ref-type="fig"}.

###### Compact gastric CA mito-signature for predicting clinical outcome

  Gene Probe ID   Symbol   Hazard-Ratio   Log-Rank Test
  --------------- -------- -------------- ---------------
  201757_at       NDUFS5   2.27           6e-10
  208844_at       VDAC3    2.22           1.4e-09
  221677_s\_at    ATP5O    2.22           2.1e-10
  200955_at       IMMT     2.20           2.4e-09
  204599_s\_at    MRPL28   2.17           1.2e-08
  213736_at       COX5B    2.14           1.4e-08
  221997_s\_at    MRPL52   2.12           3.2e-09
  208694_at       PRKDC    2.05           1.2e-07
  **Combined**             **2.77**       **1.4e-14**

![A short mitochondrial signature predicts tumor progression and overall survival in gastric cancer patients\
We combined 8 mitochondrial proteins (NDUFS5, VDAC3, ATP5O, IMMT, MRPL28, COX5B, MRPL52, PRKDC), to generate a compact gastric mitochondrial gene signature.](oncotarget-08-67117-g008){#F8}

As such, the Ga-Mito-Signature-1 represents a significant improvement over individual mitochondrial biomarkers, as well as Ki67 and PCNA.

DISCUSSION {#s3}
==========

New "druggable" targets for inhibiting mitochondrial biogenesis and blocking oxidative metabolism in cancer cells {#s3_1}
-----------------------------------------------------------------------------------------------------------------

Here, we suggest that the new mitochondrial markers that we developed here may also be useful for selecting new "druggable" targets for innovative drug development, to prevent treatment failure and improve overall survival. As a consequence of our K-M analyses, we believe that the mitochondrial ribosome would be an attractive new target for developing novel inhibitors of mitochondrial protein translation in cancer cells; similarly, mitochondrial chaperones, the OXPHOS complexes and the mitochondrial ATP-synthase may also be suitable drug targets. Particular components of these multi-subunit protein complexes show significant prognostic value, suggesting that modulation of their intrinsic activity may provide therapeutic benefits. Targeting of these large protein complexes would be predicted to suppress tumor recurrence and prevent disease progression in these gastric cancer patients.

Similarly, these mitochondrial markers could also be employed as companion diagnostics for novel therapies targeting either mitochondrial protein translation or cellular respiration, to select the high-risk sub-population of gastric cancer patients, resulting in the proper treatment stratification (Figure [9](#F9){ref-type="fig"}). In direct support of this assertion, we showed here that ∼75 different mitochondrial probes could be used to successfully identify the sub-population of high-risk gastric cancer patients. As such, these results indicate that mitochondrial markers could be used to monitor and/or predict the response to therapy, identifying patients at high-risk for treatment failure at diagnosis, several years in advance, even prior to the initiation of therapy.

![Gastric cancer: Mitochondrial-based diagnostics for personalized therapy\
In this proposed scheme, mitochondrial markers could be used to separate gastric cancer patients into high-risk and low-risk groups. Then, patients with high levels of mitochondrial markers in their primary tumor ("bad prognosis") would be treated with mitochondrial-based therapies, to prevent progression and increase survival.](oncotarget-08-67117-g009){#F9}

Cancer stem cells (CSCs) have increased mitochondrial power: diagnostic and therapeutic implications {#s3_2}
----------------------------------------------------------------------------------------------------

Recently, we identified increased mitochondrial function as a new feature of cancer stem cells (CSCs), based on unbiased proteomics analysis \[[@R7]--[@R9],[@R11]\]. This increase is mitochondrial function in CSCs may be secondary to increased mitochondrial biogenesis and/or elevated mitochondrial protein translation, resulting in the steady-state amplification of mitochondrial mass \[[@R7]--[@R9],[@R11]\]. These findings have important implications for designing new approaches for identifying and eradicating CSCs.

Importantly, our previous studies directly show that MitoTracker (a fluorescent mitochondrial vital dye) can be used, together with flow cytometry, to purify CSCs from heterogeneous populations of cancer cells \[[@R12],[@R13]\]. Importantly, the "Mito-high" cells showed the greatest functional capacity for i) anchorage-independent growth and ii) tumor-initiating activity *in vivo* \[[@R12]--[@R14]\]. Quantitatively similar results were also obtained with other mitochondrial probes (for detecting ROS and H2O2) and/or NAD(P)H auto-fluorescence, all surrogate markers of increased mitochondrial respiratory activity \[[@R14]\].

In support of these functional studies, we have also shown that FDA-approved antibiotics can be used to effectively target mitochondria in CSCs \[[@R15]--[@R21]\]. Because mitochondria evolved from aerobic bacteria, over a period \>1.5 billion years, certain types of antibiotics functionally inhibit mitochondrial biogenesis, as a manageable side-effect. In this context, tetracycline antibiotics, such as Doxycycline, appeared to be the most promising. For example, Doxcycline effectively eradicates CSCs in 12 different cell lines, representing 8 different cancer types, as well as in primary tissue samples derived from patients with advanced metastatic disease (collected from pleural effusions or ascites fluid) \[[@R15],[@R16]\].

Interestingly, these functional observations could mechanistically explain the high prognostic value of mitochondrial markers in predicting progression and survival in gastric cancer patients. Patients with high levels of mitochondrial markers may have increased levels of CSCs (Figure [9](#F9){ref-type="fig"}). As a result, these mitochondrial biomarkers could also be used as companion diagnostics, to identify which gastric cancer patients would benefit most from anti-cancer therapy with Doxycycline (or perhaps with other inhibitors of mitochondrial biogenesis and/or drugs metabolically targeting respiratory function, such as Metformin).

METHOD OF ANALYSIS {#s4}
==================

Kaplan-Meier (K-M) Analyses. To perform K-M analysis on nuclear mitochondrial gene transcripts, we used an open-access, online survival, data analysis tool to interrogate publically available microarray data from up to 1,065 gastric cancer patients \[[@R10]\]. This allowed us to determine their overall prognostic value. For this purpose, we primarily analyzed 5-year follow-up data from gastric cancer patients (N = 359). Biased array data were excluded from the analysis. This allowed us to identify ∼75 nuclear mitochondrial gene probes, with significant prognostic value. Hazard-ratios for time to first progression (FP) and overall survival (OS) were calculated, at the best auto-selected cut-off, and p-values were calculated using the logrank test and plotted in R. K-M curves were also generated online using the K-M-plotter (as high-resolution TIFF files) \[[@R10]\], using univariate analysis:

<http://kmplot.com/analysis/index.php?p=service&cancer=gastric>

This allowed us to directly perform *in silico* validation of these mitochondrial biomarker candidates.

**Author contributions**

Professor Lisanti and Dr. Sotgia conceived and initiated this project. Professor Lisanti and Dr. Sotgia both performed the bioinformatics analysis, and wrote the manuscript.

**FUNDING**

It should be noted that this bioinformatics analysis, focused on nuclear-encoded mitochondrial-related gene transcripts, was not funded by a specific grant and did not require any research expenditures, since no "wet" laboratory experiments were performed.

**CONFLICTS OF INTEREST**

MPL and FS hold a minority interest in Lunella, Inc.

CSCs

:   cancer stem-like cells
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